How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

E. G. Kamburova; B. W. Wisse; I. Joosten; W. A. Allebes; A. van der Meer; L. B. Hilbrands; M. C. Baas; E. Spierings; C. E. Hack; F. E. van Reekum; A. D. van Zuilen; M. Verhaar; M. L. Bots; A. C. A. D. Drop; L. Plaisier; M. A. J. Seelen; J. S. F. Sanders; B. G. Hepkema; A. J. Lambeck; L. B. Bungener; C. Roozendaal; M. G. J. Tilanus; J. Vanderlocht; C. E. Voorter; L. Wieten; Elly van Duijnhoven - Jansen; M. Gelens; M. H. L. Christiaans; F. J. van Ittersum; A. Nurmohamed; N. M. Lardy; W. Swelsen; K. A. van der Pant; N. C. van der Weerd; I. J. M. ten Berge; F. J. Bemelman; A. Hoitsma; P. J. M. van der Boog; J. W. de Fijter; M. G. H. Betjes; S. Heidt; D. L. Roelen; F. H. Claas; H. G. Otten

doi:10.1111/tan.12860

How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

E. G. Kamburova^*, B. W. Wisse, I. Joosten, W. A. Allebes, A. van der Meer, L. B. Hilbrands, M. C. Baas, E. Spierings, C. E. Hack, F. E. van Reekum, A. D. van Zuilen, M. Verhaar, M. L. Bots, A. C. A. D. Drop, L. Plaisier, M. A. J. Seelen, J. S. F. Sanders, B. G. Hepkema, A. J. Lambeck, L. B. BungenerC. Roozendaal, M. G. J. Tilanus, J. Vanderlocht, C. E. Voorter, L. Wieten, Elly van Duijnhoven - Jansen, M. Gelens, M. H. L. Christiaans, F. J. van Ittersum, A. Nurmohamed, N. M. Lardy, W. Swelsen, K. A. van der Pant, N. C. van der Weerd, I. J. M. ten Berge, F. J. Bemelman, A. Hoitsma, P. J. M. van der Boog, J. W. de Fijter, M. G. H. Betjes, S. Heidt, D. L. Roelen, F. H. Claas, H. G. Otten

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Solid-phase multiplex-bead assays are widely used in transplantation to detect anti-human leukocyte antigen (HLA) antibodies. These assays enable high resolution detection of low levels of HLA antibodies. However, multiplex-bead assays are costly and yield variable measurements that limit the comparison of results between laboratories. In the context of a Dutch national Consortium study we aimed to determine the inter-assay and inter-machine variability of multiplex-bead assays, and we assessed how to reduce the assay reagents costs. Fifteen sera containing a variety of HLA antibodies were used yielding in total 7092 median fluorescence intensities (MFI) values. The inter-assay and inter-machine mean absolute relative differences (MARD) of the screening assay were 12% and 13%, respectively. The single antigen bead (SAB) inter-assay MARD was comparable, but showed a higher lot-to-lot variability. Reduction of screening assay reagents to 50% or 40% of manufacturers' recommendations resulted in MFI values comparable to 100% of the reagents, with an MARD of 12% or 14%, respectively. The MARD of the 50% and 40% SAB assay reagent reductions were 11% and 22%, respectively. From this study, we conclude that the reagents can be reliably reduced at least to 50% of manufacturers' recommendations with virtually no differences in HLA antibody assignments.

Original language	English
Pages (from-to)	110-119
Journal	HLA
Volume	88
Issue number	3
DOIs	https://doi.org/10.1111/tan.12860
Publication status	Published - Sept 2016

Keywords

human leukocyte antigen antibodies
luminex
single antigen
solid-phase multiplex-bead assays

Access to Document

10.1111/tan.12860

Cite this

Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M., Bots, M. L., Drop, A. C. A. D., Plaisier, L., Seelen, M. A. J., Sanders, J. S. F., Hepkema, B. G., Lambeck, A. J., ... Otten, H. G. (2016). How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies? HLA, 88(3), 110-119. https://doi.org/10.1111/tan.12860

@article{dc4f6203132c4f518634a877d35c1b75,

title = "How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?",

abstract = "Solid-phase multiplex-bead assays are widely used in transplantation to detect anti-human leukocyte antigen (HLA) antibodies. These assays enable high resolution detection of low levels of HLA antibodies. However, multiplex-bead assays are costly and yield variable measurements that limit the comparison of results between laboratories. In the context of a Dutch national Consortium study we aimed to determine the inter-assay and inter-machine variability of multiplex-bead assays, and we assessed how to reduce the assay reagents costs. Fifteen sera containing a variety of HLA antibodies were used yielding in total 7092 median fluorescence intensities (MFI) values. The inter-assay and inter-machine mean absolute relative differences (MARD) of the screening assay were 12% and 13%, respectively. The single antigen bead (SAB) inter-assay MARD was comparable, but showed a higher lot-to-lot variability. Reduction of screening assay reagents to 50% or 40% of manufacturers' recommendations resulted in MFI values comparable to 100% of the reagents, with an MARD of 12% or 14%, respectively. The MARD of the 50% and 40% SAB assay reagent reductions were 11% and 22%, respectively. From this study, we conclude that the reagents can be reliably reduced at least to 50% of manufacturers' recommendations with virtually no differences in HLA antibody assignments.",

keywords = "human leukocyte antigen antibodies, luminex, single antigen, solid-phase multiplex-bead assays",

author = "Kamburova, {E. G.} and Wisse, {B. W.} and I. Joosten and Allebes, {W. A.} and {van der Meer}, A. and Hilbrands, {L. B.} and Baas, {M. C.} and E. Spierings and Hack, {C. E.} and {van Reekum}, {F. E.} and {van Zuilen}, {A. D.} and M. Verhaar and Bots, {M. L.} and Drop, {A. C. A. D.} and L. Plaisier and Seelen, {M. A. J.} and Sanders, {J. S. F.} and Hepkema, {B. G.} and Lambeck, {A. J.} and Bungener, {L. B.} and C. Roozendaal and Tilanus, {M. G. J.} and J. Vanderlocht and Voorter, {C. E.} and L. Wieten and {van Duijnhoven - Jansen}, Elly and M. Gelens and Christiaans, {M. H. L.} and {van Ittersum}, {F. J.} and A. Nurmohamed and Lardy, {N. M.} and W. Swelsen and {van der Pant}, {K. A.} and {van der Weerd}, {N. C.} and {ten Berge}, {I. J. M.} and Bemelman, {F. J.} and A. Hoitsma and {van der Boog}, {P. J. M.} and {de Fijter}, {J. W.} and Betjes, {M. G. H.} and S. Heidt and Roelen, {D. L.} and Claas, {F. H.} and Otten, {H. G.}",

year = "2016",

month = sep,

doi = "10.1111/tan.12860",

language = "English",

volume = "88",

pages = "110--119",

journal = "HLA",

issn = "2059-2302",

publisher = "Wiley",

number = "3",

}

Kamburova, EG, Wisse, BW, Joosten, I, Allebes, WA, van der Meer, A, Hilbrands, LB, Baas, MC, Spierings, E, Hack, CE, van Reekum, FE, van Zuilen, AD, Verhaar, M, Bots, ML, Drop, ACAD, Plaisier, L, Seelen, MAJ, Sanders, JSF, Hepkema, BG, Lambeck, AJ, Bungener, LB, Roozendaal, C, Tilanus, MGJ, Vanderlocht, J, Voorter, CE , Wieten, L , van Duijnhoven - Jansen, E , Gelens, M , Christiaans, MHL, van Ittersum, FJ, Nurmohamed, A, Lardy, NM, Swelsen, W, van der Pant, KA, van der Weerd, NC, ten Berge, IJM, Bemelman, FJ, Hoitsma, A, van der Boog, PJM, de Fijter, JW, Betjes, MGH, Heidt, S, Roelen, DL, Claas, FH & Otten, HG 2016, 'How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?', HLA, vol. 88, no. 3, pp. 110-119. https://doi.org/10.1111/tan.12860